Japan’s Takeda Pharmaceutical (TSE: 4502) and TiGenix (Euronext Brussels: TIG) have announced that at the end of the second acceptance period, Takeda will hold over 96% of all ordinary shares of the Belgian biotech.
Takeda launched its takeover of the company in January with an offer worth some $630 million, before attention turned to its brobdingnagian bid for London-listed Shire (LSE: SHP).
The Japanese firm hopes to leverage TiGenix’s expertise to accelerate development of novel stem cell therapies, including Cx601 (darvadstrocel), for the treatment of complex perianal fistulas in Crohn’s disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze